Roquefort Therapeutics (LON:ROQ) Shares Down 10% – Here’s Why

Shares of Roquefort Therapeutics plc (LON:ROQ) traded down 10% during trading on Tuesday . The company traded as low as GBX 1.26 and last traded at GBX 1.26. 100,000 shares changed hands during trading, a decline of 96% from the average session volume of 2,249,489 shares. The stock had previously closed at GBX 1.40.

Roquefort Therapeutics Trading Down 1.0%

The firm has a market capitalization of £2.03 million, a price-to-earnings ratio of -2.04 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79. The business has a fifty day moving average price of GBX 1.78 and a 200 day moving average price of GBX 1.70.

Roquefort Therapeutics (LON:ROQ) last posted its quarterly earnings results on Tuesday, September 30th. The company reported GBX (0.33) earnings per share (EPS) for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 29.57%.

Insider Buying and Selling

In other Roquefort Therapeutics news, insider Dr Darrin Disley purchased 5,000,000 shares of Roquefort Therapeutics stock in a transaction on Friday, November 21st. The shares were purchased at an average cost of GBX 170 per share, with a total value of £8,500,000. Insiders own 23.53% of the company’s stock.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.